Nephrolithiasis

Nephrolithiasis (kidney stone disease) is the formation of crystalline deposits within the renal collecting system, representing a common urological emergency affecting approximately 1 in 11 Americans with an annual incidence of 1.5-4 per 1,000 population and prevalence of 3-5%. The disease demonstrates strong geographic and demographic variation, with higher prevalence in hot climates, Caucasian populations, males (2-3:1 ratio), and typically presents in the fourth to sixth decades of life. Recurrence rates are substantial, ranging from 15% at 1 year to 50% at 10 years without preventive intervention, making this a chronic relapsing condition with significant morbidity and economic impact. Clinical significance derives from the acute complications (obstruction, infection, renal function loss), chronic kidney disease progression in susceptible populations, and the high percentage of stone formers with underlying metabolic abnormalities amenable to targeted prevention. Understanding stone pathogenesis, composition analysis, and metabolic evaluation is essential for appropriate acute management and long-term prevention strategies tested extensively on board examinations.

The fundamental mechanism underlying stone formation is sustained urinary supersaturation with respect to stone-forming substances. In normal conditions, urine maintains a delicate solubility equilibrium through complexation (citrate, magnesium, and other inhibitors binding to calcium and uric acid) and dilute urine flow. When concentration of stone-forming solutes (calcium oxalate, calcium phosphate, uric acid, struvite) exceeds the solubility product, the solution becomes supersaturated. This creates a thermodynamically unfavorable state where homogeneous nucleation (spontaneous formation of crystal clusters from solution without a surface template) becomes possible. The activation energy for crystal formation is reduced substantially in acidic urine (favoring uric acid, cystine precipitation) and alkaline urine (favoring calcium phosphate, struvite), explaining why urine pH strongly influences stone type and formation risk.

Rather than spontaneous precipitation from pure solution, heterogeneous nucleation (crystal formation on an organic or inorganic template) is the predominant mechanism in vivo. Crystalline matrix proteins (osteopontin, Tamm-Horsfall protein, calgranulin) serve as nucleation sites where crystal growth proceeds with lower activation energy than homogeneous nucleation. Calcium oxalate monohydrate (COM) crystals, the most thermodynamically stable and common stone form, exhibit preferential growth on specific protein epitopes. Once nucleation occurs, crystal growth continues through addition of more solute to the developing crystal lattice, with growth kinetics proportional to the degree of supersaturation and duration of exposure. This explains why chronic mild supersaturation produces gradual stone enlargement, while acute dramatic elevations in solute concentration (e.g., acute uric acid release from tumor lysis) produce rapid stone formation.

Urine pH fundamentally determines the ionization state and solubility of weak acids and bases, thereby controlling stone formation propensity for multiple stone types. Uric acid (pKa 5.75) exists predominantly in the ionized, soluble urate form at physiologic pH 7.4, but becomes protonated and precipitates in acidic urine (pH <6.0), explaining why hyperuricemia becomes pathologic only when associated with urine acidification. Calcium phosphate (primarily HPO₄²⁻ at physiologic pH) increases sharply in alkaline urine as pH rises above 6.5, with the solubility product inversely proportional to [H⁺], making alkaline urine a risk factor for phosphate stones. Cystine, a dibasic amino acid with pKa 8.3 for the second ionizable group, remains poorly soluble even at neutral pH due to its unique chemistry, producing characteristically radiopaque, crystalline stones in homozygous cystinuria. Conversely, ammonia/ammonium equilibrium shifts toward ammonia gas (volatile) in alkaline urine and ammonium salt in acidic urine, influencing struvite (magnesium ammonium phosphate) formation in infected, alkaline urine.

The concentration and activity of endogenous stone inhibitors inversely correlate with stone formation risk, comprising a critical protective mechanism frequently disrupted in stone formers. Citrate is the most important inhibitor, functioning through dual mechanisms: (1) complexation of free calcium, reducing its bioavailability for crystal formation and (2) direct inhibition of crystal nucleation and growth through binding to crystal surfaces. Citrate metabolism is insulin-dependent (acidosis, hypokalemia, and thiazide diuretics reduce urinary citrate), explaining why these conditions dramatically increase stone risk despite normal serum calcium. Magnesium similarly complexes calcium oxalate and urate, and deficiency (from diarrhea, dietary restriction) unmasks supersaturation. Nephrocalcin (osteopontin and other acidic proteins) and Tamm-Horsfall protein (uromodulin) inhibit crystal growth kinetics and promote crystal aggregation into larger structures that can pass spontaneously. Genetic polymorphisms affecting inhibitor production (e.g., low citrate excreters) or function explain familial clustering of stone disease independent of single-gene disorders.

Recent evidence reveals that chronic crystal-cell interactions provoke inflammatory changes in the renal interstitium and collecting system, perpetuating stone formation cycles. Calcium oxalate crystals directly injure renal tubular epithelium through oxidative stress and mitochondrial dysfunction, triggering inflammatory cytokine release (TNF-α, IL-6, IL-8). Injured epithelial cells upregulate osteopontin expression, creating a pathologic positive feedback loop where inflammatory response generates more inhibitor-binding substrate that nucleates additional crystals. Endocytosis of crystals by renal epithelial cells activates intracellular inflammasome pathways, generating crystalline deposits in the interstitium that propagate stone formation at the crystal-embedding sites (CES) where Randall's plaques (calcium phosphate deposits in vasa recta) become sites of subsequent calcium oxalate nucleation. This model explains why stone formers demonstrate chronic tubulointerstitial inflammation, progressive renal fibrosis, and declining glomerular filtration rate over time independent of acute obstruction.

Monogenic disorders account for approximately 5-10% of stone disease, with the remainder reflecting polygenic inheritance plus environmental triggers. Primary hyperparathyroidism causes 5-10% of calcium-containing stones through elevated PTH-stimulated renal calcium reabsorption and 1,25-vitamin D production. Distal renal tubular acidosis (Type 1 RTA) causes alkaline urine and hypocitraturia through impaired H⁺ secretion in the collecting duct, producing predominantly calcium phosphate stones in 40-60% of untreated patients. Cystinuria (autosomal recessive mutations in SLC3A1 encoding the apical cystine transporter rBAT) causes massive urinary cystine excretion (>400 mg/day vs normal <40 mg/day), with stone formation inevitable by adolescence without preventive measures. Medullary sponge kidney (collecting duct ectasia, sporadic or autosomal dominant) creates stagnant urine pockets promoting calcification in 20% of patients. Polygenic conditions predisposing to stone formation include genetic variants affecting ammonia metabolism, citrate synthesis pathways (AGXT mutations in primary hyperoxaluria), and intestinal oxalate absorption genes.

Hypercalciuria (urine calcium >250 mg/day in women, >300 mg/day in men) is present in 40-50% of recurrent calcium stone formers and represents the most common modifiable risk factor. Three pathophysiological categories exist: (1) Absorptive hypercalciuria (Type I, most common, 30-40% of stone formers) characterized by increased intestinal calcium absorption due to elevated 1,25-vitamin D (either genetically determined high conversion rate or secondary to high dietary calcium intake paradoxically), with normal parathyroid hormone, normal serum calcium, but elevated urinary calcium even during fasting; (2) Renal hypercalciuria (Type II) reflecting primary renal tubular calcium leak despite normal intestinal absorption and normal PTH, often familial; and (3) Resorptive hypercalciuria associated with primary hyperparathyroidism or vitamin D intoxication, where elevated PTH drives both hypercalcemia and hypercalciuria. The pathophysiology invariably leads to supersaturation of calcium oxalate and calcium phosphate in the distal tubule and collecting duct where concentration is maximal.

Hyperoxaluria (urinary oxalate >40-45 mg/day) occurs through three distinct mechanisms: (1) Primary hyperoxaluria, comprising three autosomal recessive genetic subtypes (Type 1 from AGXT mutations causing alanine-glyoxylate aminotransferase deficiency, Type 2 from GRHPR mutations, Type 3 from HOGA1 mutations), each causing massive endogenous oxalate production (300-1,000+ mg/day) with inevitable early-onset nephrolithiasis and chronic kidney disease; (2) Secondary hyperoxaluria from dietary oxalate excess (spinach, rhubarb, beets, nuts, chocolate, tea contain 5-50 mg/serving), enhanced in fat malabsorption states where fatty acids form soaps with calcium, reducing luminal calcium available to bind oxalate, thereby increasing oxalate absorption (seen in inflammatory bowel disease, short-bowel syndrome, cystic fibrosis, pancreatic insufficiency); and (3) Enteric hyperoxaluria specifically in patients with jejunal or ileal disease/bypass where increased intestinal transit time and increased oxalate-binding bacterial flora promote oxalate absorption. Oxalate is an end-product of metabolism incapable of further degradation, making urinary excretion the sole means of elimination, explaining why even modest elevations dramatically increase stone risk.

Hyperuricemia (serum uric acid >6.8-7.0 mg/dL) and hyperuricosuria (urine uric acid >800 mg/day in men, >750 mg/day in women) occur through increased production or decreased renal excretion, both favoring uric acid stone formation. Overproduction occurs with increased purine metabolism (from high meat/seafood diet, gout, myeloproliferative disease, tumor lysis syndrome, enzyme defects like HGPRT deficiency or phosphoribosylpyrophosphate synthetase overactivity). However, urine pH is the critical determinant of uric acid solubility: uric acid stones form almost exclusively at pH <5.5, explaining why hyperuricemia alone is insufficient for stone formation unless accompanied by urine acidification. Conditions causing chronic urine acidification (high protein diet, chronic diarrhea, renal tubular acidosis Type 1, and certain medications) create the permissive environment for uric acid precipitation. Notably, many patients with uric acid stones have normal serum and urine uric acid levels but abnormally acidic urine, highlighting the primacy of pH in pathogenesis.

Primary hyperparathyroidism accounts for 5-10% of calcium-containing stones through three mechanisms: (1) elevated PTH directly increases renal tubular calcium reabsorption; (2) PTH stimulates 1,25-vitamin D production, increasing intestinal calcium absorption; and (3) PTH suppresses serum phosphate, increasing the filtered load and renal reabsorption of calcium. Patients with primary hyperparathyroidism demonstrate hypercalcemia (ionized calcium >5.5 mg/dL), hypercalciuria, and persistently elevated or inappropriately normal PTH levels despite hypercalcemia. Vitamin D intoxication (from excessive supplementation, granulomatous disease like sarcoidosis, lymphoma) causes hypercalcemia through extrarenal 1,25-vitamin D production and PTH suppression, with similar stone-forming consequences. Thyrotoxicosis accelerates bone turnover and osteoclastic resorption, increasing circulating calcium and filtered load. Immobilization, particularly in young patients with high bone turnover rates, causes transient hypercalcemia and hypercalciuria through increased osteoclastic activity unopposed by weight-bearing osteoblast stimulation.

Distal (Type 1) RTA causes hypokalemic hyperchloremic metabolic acidosis through impaired distal tubular H⁺ secretion, creating persistently alkaline urine (pH >5.5 despite systemic acidosis—the pathognomonic "paradoxical aciduria" finding). The alkaline urine directly promotes calcium phosphate and magnesium ammonium phosphate precipitation, while acidosis simultaneously reduces urinary citrate excretion (citrate reabsorption increases in acidosis), eliminating the inhibitor. Approximately 40-60% of untreated Type 1 RTA patients develop nephrolithiasis, often with recurrent infections from struvite stone debris. Chronic kidney disease increases stone risk through multiple mechanisms: (1) reduced citrate excretion from impaired proximal reabsorption; (2) hyperphosphatemia causing secondary hyperparathyroidism and altered mineral metabolism; (3) medication use (loop diuretics reducing urine volume, acetazolamide alkalinizing urine); and (4) reduced 1,25-vitamin D production reducing intestinal calcium absorption but increasing parathyroid hyperplasia.

Cystinuria (autosomal recessive mutations in SLC3A1 or SLC7A9 genes encoding renal cystine transporter components rBAT and y+LAT1) causes massive urinary cystine excretion (>400 mg/day, normal <40 mg/day) leading to early-onset stone formation in 60-80% of homozygotes by age 30. Cystine crystals form characteristically at pH 5.5-6.0 and are positively identifiable on urine microscopy or stone analysis as pathognomonic hexagonal crystals. Medullary sponge kidney, either autosomal dominant or sporadic (associated with GNAS mutations), causes localized collecting duct ectasia with retained fluid and calcification in 10-20% of affected patients, often presenting with hematuria or stone passage rather than true recurrent stone formation. Bartter and Gitelman syndromes (inherited tubulopathies affecting sodium-potassium-chloride cotransport) cause hypokalemic metabolic alkalosis with hypercalciuria, predisposing to nephrolithiasis despite young age.

High sodium intake (>3,500 mg/day) increases urinary sodium and causes secondary hypercalciuria through reduced proximal tubular calcium reabsorption; sodium and calcium share the paracellular reabsorption pathway, making sodium-induced natriuresis obligately coupled to calciuria. High animal protein diet (>1.5 g/kg/day) increases uric acid and cystine excretion while decreasing urinary citrate through acidification of urine; sulfur amino acids (methionine, cysteine) from meat are oxidized to sulfate, which obligately accompanies ammonium excretion and lowers urine pH. Low dietary calcium (<800 mg/day) paradoxically increases stone risk despite lower filtered calcium load, because low luminal calcium fails to bind intestinal oxalate, increasing oxalate absorption and urinary excretion by 20-40%; this explains why dietary calcium restriction is counterproductive. Low urinary citrate (<100 mg/day) from chronic acidosis, hypokalemia, or thiazide use removes the principal inhibitor of crystallization. Dehydration and low urine output (<1,500 mL/day) concentrate all solutes, raising supersaturation regardless of the absolute amount excreted. Medications including thiazide diuretics (paradoxically reduce hypercalciuria but increase hypokalemia and hypocitraturia, net stone-protective effect despite mixed signals), loop diuretics (increase hypercalciuria), acetazolamide (alkalinizes urine), **amphotericin

Size thresholds that matter: stones <5 mm usually pass spontaneously; ≥10 mm rarely do and generally require intervention.

Metabolic workup: send the stone for composition analysis. AUA recommends a 24-hour urine study (volume, calcium, oxalate, citrate, uric acid, sodium, pH, cystine) in recurrent stone formers and high-risk first-time formers.